INDIANAPOLIS (AP) _ Growing sales of Prozac, the antipsychotic agent Zyprexa and the osteoporosis drug Evista keyed a 17 percent rise in second-quarter earnings at Eli Lilly and Co., it reported today.

Lilly earned $576.4 million, or 52 cents per share, during the April-June period, compared with earnings of $491.3 million, or 44 cents per share, during the second quarter a year ago. The latest per-share results were a penny above the consensus estimates by industry analysts.

Sales rose 9 percent to $2.34 billion, compared with $2.16 billion in the year-ago period.

Leading the way was 4 percent sales growth by Prozac to $688.1 million. U.S. sales accounted for 82 percent of the market, while overseas sales fell 7 percent, partly because of generic competition.

Zyprexa sales rose 20 percent to $393.0 million. Lilly said sales were growth suffered from overstocking wholesalers at the end of 1998.

Evista sales rose 22 percent during the latest quarter from the first three months of 1999, reaching $66.6 million. The drug currently marketed to prevent osteoporosis, but the U.S. Food and Drug Administration has given the compound priority review status that eventually could allow Lilly to market it as a treatment for the brittle-bone disease.

However, a federal judge in New York ordered Lilly last week to stop promoting Evista as a prevention for breast cancer. Studies on Evista's potential cancer-fighting abilities are ongoing.

Sales of the anticlotting medicine ReoPro rose 13 percent from the year-ago period to $114.2 million. Lilly's partner in selling the anti-clotting agent, Centocor, announced today it was being acquired by Johnson & Johnson in a $4.9 billion stock deal.

The FDA last week gave marketing approval to a new diabetes drug, Actos, that Lilly will co-market in the United States with its developer, the Japanese drug company Takeda Chemicals Industries Ltd.

During the first half of 1999, Lilly's net income rose 19 percent to $1.20 billion, or $1.08 per share, from $1.01 billion, or 90 cents per share. Sales rose 8 percent to $4.59 billion.